Filing identity and reporting period
Material metadata discrepancy: The supplied filing is Isoray, Inc.’s Form 10-Q for the quarter ended March 31, 2020, covering its fiscal third quarter and nine months ended that date. It is not identified in the filing as a Perspective Therapeutics filing or a 2019 Q3 report. The summary below reflects the filing text provided.
Business context and financial results
Isoray manufactures and sells Cesium-131 brachytherapy seeds and related products, including Cesium Blu. Its sales are predominantly U.S.-based; prostate brachytherapy represented 84% of quarterly revenue and 87% of nine-month revenue.
| Metric | Three months ended March 31, 2020 | Nine months ended March 31, 2020 |
|---|---|---|
| Net sales | $2.88 million, up 50% year over year | $7.40 million, up 37% |
| Gross profit / margin | $1.71 million / 59% (46% prior year) | $4.05 million / 55% (40% prior year) |
| Operating loss | $0.55 million, versus $1.16 million | $2.29 million, versus $4.11 million |
| Net loss | $0.55 million, versus $1.13 million | $2.26 million, versus $4.05 million |
| Loss per share | $0.01 | $0.03 |
| Operating cash flow | Not separately reported for the quarter | -$2.79 million, versus -$4.06 million |
At March 31, 2020, cash and cash equivalents were $2.41 million (June 30, 2019: $5.33 million); working capital was $3.98 million and the current ratio was 3.28. Total liabilities were $3.14 million, including $1.06 million of lease liabilities. Management reported no long-term debt. Shareholders’ equity was $5.82 million, down from $7.68 million at June 30, 2019.
Material changes and management commentary
- Revenue growth reflected new accounts, greater orders from existing customers, January 2020 price increases, and growth in both prostate and other applications. Other sales grew 103% in the quarter and 52% over nine months.
- Gross margin improved substantially, which management attributed to increased sales, lower isotope unit costs following a supply-chain change, fixed-cost leverage, and more efficient isotope use.
- Operating expenses rose 10% in the quarter, including higher sales and marketing costs; nine-month operating expenses were broadly flat year over year.
- COVID-19-related procedure cancellations affected March sales; preliminary April revenue was approximately 20% below April 2019. Management reported accelerating orders from late April as procedures were rescheduled, but said recovery was uncertain.
- COVID-19 also disrupted parts supply for the Blu Build loader. Management expected a slower-than-planned release through the rest of fiscal 2020, with continued revenue contribution in Q4 and potential traction in fiscal 2021, subject to further supply delays.
Outlook, liquidity, and risks
- Management said cash reserves were sufficient to fund operations through the remainder of calendar 2020. Under assumptions including continued revenue growth and no extraordinary expenses, it estimated cash-flow break-even in about three years; it cautioned there is no assurance growth will continue.
- The company exceeded its stated 25% fiscal 2020 revenue-growth target over the first nine months. This is not a guarantee of full-year results.
- Management may seek additional capital through equity, strategic collaborations, debt, or other sources. The March 31 ATM agreement with Oppenheimer allowed sales at prevailing market prices for a 3% commission; no shares had been sold under it by March 31.
- Equity of $5.82 million was below the filing’s stated $6 million NYSE American threshold. The company warned it may need to raise capital within 12–18 months to maintain listing eligibility; additional financing could dilute shareholders.
- Three customers accounted for approximately 40% of nine-month revenue, with one accounting for approximately 25%. The filing also identifies Russian Cesium-131 supply, COVID-related demand and logistics disruption, and uncertain reimbursement and adoption for non-prostate procedures as risks.
- The company’s Russian isotope supply contract ran through December 2020. A Russian reactor remained shut down for an indeterminate period, and management noted potential supply and transport interruptions.
- Other notable items: the company recognized a $73,000 gain from a revised asset-retirement estimate following a lease extension; it adopted lease accounting and recorded a right-of-use asset and lease liability of approximately $1.2 million.
Most important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied filing is Isoray’s March 31, 2020 10-Q, not Perspective Therapeutics’ 2019 Q3 filing.
- Track cash burn, the stated calendar-2020 funding runway, and any subsequent capital raises or ATM sales.
- Monitor equity against NYSE American listing requirements and assess potential dilution from financing.
- Verify whether COVID-related procedure delays and Blu Build component shortages resolved as management anticipated.
- Assess customer concentration and continuity of Cesium-131 supply from Russia.